Abituzumab
Abituzumab
Abituzumab (pronounced as a-bi-tu-zu-mab) is a monoclonal antibody designed for the treatment of various cancer types and fibrosis. It is currently under clinical trials.
Etymology
The name "Abituzumab" is derived from the International Nonproprietary Naming (INN) system for pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, while the "tuzu-" stem suggests its action against tumors.
Mechanism of Action
Abituzumab works by targeting and inhibiting the integrin family of proteins, which are involved in cell adhesion and migration, processes that are crucial for the growth and spread of cancer cells.
Clinical Trials
Abituzumab has been tested in several clinical trials for its effectiveness against various types of cancer, including colorectal cancer, prostate cancer, and lung cancer. It has also been studied for its potential use in treating fibrosis.
Related Terms
- Monoclonal antibody
- Cancer
- Fibrosis
- Integrin
- Clinical trial
- Colorectal cancer
- Prostate cancer
- Lung cancer
External links
- Medical encyclopedia article on Abituzumab
- Wikipedia's article - Abituzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski